Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size, Share, Trends and Forecast 2022-2030

Description

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man's life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
Industry Insights

Due to the COVID-19 pandemic, the global Benign Prostatic Hyperplasia (BPH) Drugs market size is estimated to be worth US$ 3329.5 million in 2021 and is forecast to a readjusted size of US$ 4195.1 million by 2028 with a CAGR of 3.3% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Benign Prostatic Hyperplasia (BPH) Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Benign Prostatic Hyperplasia (BPH) Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

This report focuses on Benign Prostatic Hyperplasia (BPH) Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Benign Prostatic Hyperplasia (BPH) Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Benign Prostatic Hyperplasia (BPH) Drugs market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

Alpha-Blocker

Phosphodiesterase Type-5 Inhibitors

Others

Segment by Application

Hospitals

Drugstores

Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Eli Lilly

GlaxoSmithKline

Astellas Pharma

Sanofi

Pfizer

Abbott

Allergan

TEVA

Mylan

Novartis

Merck

TABLE OF CONTENT

1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs

1.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type

1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Comparison by Type (2022-2028)

1.2.2 Alpha-Blocker

1.2.3 Phosphodiesterase Type-5 Inhibitors

1.2.4 Others

1.3 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application

1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Comparison by Application: (2022-2028)

1.3.2 Hospitals

1.3.3 Drugstores

1.3.4 Others

1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts

1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2017-2028

1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2017-2028

1.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2017 Versus 2021 Versus 2028

2 Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by Manufacturers

2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2017-2022)

2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2017-2022)

2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2017-2022)

2.4 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Sites, Area Served, Product Type

2.5 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends

2.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue

2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario by Region

3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country

3.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country

3.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country

3.3.3 U.S.

3.3.4 Canada

3.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country

3.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country

3.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Region

3.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region

3.5.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.5.12 Philippines

3.5.13 Vietnam

3.6 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country

3.6.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country

3.6.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.7 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country

3.7.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country

3.7.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Analysis by Type

4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2022)

4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2017-2022)

4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2017-2022)

5 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Analysis by Application

5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2022)

5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2017-2022)

5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2017-2022)

6 Key Companies Profiled

6.1 Eli Lilly

6.1.1 Eli Lilly Corporation Information

6.1.2 Eli Lilly Description and Business Overview

6.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

6.1.5 Eli Lilly Recent Developments/Updates

6.2 GlaxoSmithKline

6.2.1 GlaxoSmithKline Corporation Information

6.2.2 GlaxoSmithKline Description and Business Overview

6.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

6.2.5 GlaxoSmithKline Recent Developments/Updates

6.3 Astellas Pharma

6.3.1 Astellas Pharma Corporation Information

6.3.2 Astellas Pharma Description and Business Overview

6.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

6.3.5 Astellas Pharma Recent Developments/Updates

6.4 Sanofi

6.4.1 Sanofi Corporation Information

6.4.2 Sanofi Description and Business Overview

6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

6.4.5 Sanofi Recent Developments/Updates

6.5 Pfizer

6.5.1 Pfizer Corporation Information

6.5.2 Pfizer Description and Business Overview

6.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

6.5.5 Pfizer Recent Developments/Updates

6.6 Abbott

6.6.1 Abbott Corporation Information

6.6.2 Abbott Description and Business Overview

6.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

6.6.5 Abbott Recent Developments/Updates

6.7 Allergan

6.6.1 Allergan Corporation Information

6.6.2 Allergan Description and Business Overview

6.6.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

6.7.5 Allergan Recent Developments/Updates

6.8 TEVA

6.8.1 TEVA Corporation Information

6.8.2 TEVA Description and Business Overview

6.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

6.8.5 TEVA Recent Developments/Updates

6.9 Mylan

6.9.1 Mylan Corporation Information

6.9.2 Mylan Description and Business Overview

6.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

6.9.5 Mylan Recent Developments/Updates

6.10 Novartis

6.10.1 Novartis Corporation Information

6.10.2 Novartis Description and Business Overview

6.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

6.10.5 Novartis Recent Developments/Updates

6.11 Merck

6.11.1 Merck Corporation Information

6.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Description and Business Overview

6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio

6.11.5 Merck Recent Developments/Updates

7 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Analysis

7.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

7.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors List

8.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers

9 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics

9.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends

9.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers

9.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges

9.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints

10 Global Market Forecast

10.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2023-2028)

10.1.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2023-2028)

10.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Application

10.2.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2023-2028)

10.2.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2023-2028)

10.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2023-2028)

10.3.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample